Immune checkpoint inhibitor therapy, which activates T cells to kill tumor cells, is an effective way to treat some cancer types.
A team of Roswell Park Comprehensive Cancer Center researchers has identified a new biomarker that could predict response to immune checkpoint inhibitors (ICI) shortly after patients with non-small cell lung cancer (NSCLC) initiate therapy.
At Roswell Park Comprehensive Cancer Center, Philip McCarthy, MD, Director of the Transplant and Cellular Therapy Center in the Department of Medicine, and a multidisciplinary team of colleagues recently undertook a study to understand ...
Many of the most aggressive and hard-to-treat cancers are highly effective at blocking T cells, known as the foot soldiers of the immune system, from reaching and responding to tumors. It’s a cancer defense mechanism that even groundbreaking ...
This site is intended for healthcare professionals